SBI Securities Co. Ltd. Acquires Shares of 34,485 Novavax, Inc. (NASDAQ:NVAX)

SBI Securities Co. Ltd. bought a new stake in shares of Novavax, Inc. (NASDAQ:NVAX) during the 4th quarter, HoldingsChannel.com reports. The fund bought 34,485 shares of the biopharmaceutical company’s stock, valued at approximately $277,000.

Several other hedge funds also recently modified their holdings of NVAX. State Street Corp boosted its position in shares of Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock valued at $97,099,000 after buying an additional 1,621,772 shares during the last quarter. Shah Capital Management boosted its position in shares of Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock valued at $89,637,000 after buying an additional 1,333,305 shares during the last quarter. Two Sigma Advisers LP boosted its position in shares of Novavax by 48.9% during the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock valued at $25,252,000 after buying an additional 656,900 shares during the last quarter. Bank of Montreal Can boosted its position in shares of Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock valued at $32,643,000 after buying an additional 517,727 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Novavax by 9.5% during the third quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock valued at $44,245,000 after buying an additional 304,159 shares during the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Trading Up 2.7 %

Shares of Novavax stock opened at $7.89 on Thursday. The business’s fifty day simple moving average is $8.47 and its 200 day simple moving average is $9.86. The firm has a market capitalization of $1.26 billion, a P/E ratio of -3.49, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. Novavax, Inc. has a 12 month low of $3.81 and a 12 month high of $23.86.

Novavax (NASDAQ:NVAX) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the previous year, the firm earned ($1.44) earnings per share. Analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Insider Buying and Selling at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $9.02, for a total value of $37,433.00. Following the sale, the director now directly owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James F. Young sold 5,400 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total value of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at approximately $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 over the last ninety days. 1.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

NVAX has been the topic of several analyst reports. TD Cowen raised Novavax to a “hold” rating in a research report on Thursday, February 27th. BTIG Research initiated coverage on Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $18.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.